You are here

Topiglan Study Fails To Meet Primary Endpoint

LEXINGTON, Mass., April 14 /PRNewswire/ -- MacroChem Corporation (NASDAQ: MCHM) announced today that preliminary data from its Phase 2 pharmacodynamic study of Topiglan(R), a topical cream for erectile dysfunction, demonstrate that Topiglan did not meet the study's primary clinical endpoints. The randomized, double-blind clinical study, which utilized the RigiScan(R) monitoring technique, compared the efficacy of Topiglan in men with mild-to- moderate erectile dysfunction to a placebo cream.

"While we are disappointed by these preliminary Topiglan data, we continue to advance our clinical studies of EcoNail(TM) and Opterone(TM)," said Robert J. DeLuccia, chief executive officer of MacroChem. "We plan in the weeks ahead to further analyze all of the Topiglan study data."

MacroChem currently has two other clinical programs underway. A dose- proportionality study of Opterone cream, an absorption-enhanced topical treatment for male testosterone deficiency, is ongoing. Patients are currently being dosed and results from that study are expected later this year. The Company has also initiated a Phase 1 study of EcoNail in patients with onychomycosis, a fungal infection of nails. Patient screening is nearly complete and data from this study are expected to be available by the end of the year.

Source: Macrochem

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress